Cargando…

Correction: Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510914/ https://www.ncbi.nlm.nih.gov/pubmed/28856062 http://dx.doi.org/10.1371/currents.hd.976177e0cbf724437ea11745c9231a57

Ejemplares similares

Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease
por: Chen, Jane Y., et al.
Publicado: (2013)

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo
por: Beconi, Maria, et al.
Publicado: (2012)

Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse Model
por: Rai, Myriam, et al.
Publicado: (2010)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs)
por: Mackmull, Marie-Therese, et al.
Publicado: (2015)

Case of Pimelitis
por: Gill, Railton
Publicado: (1842)

Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington’s disease
por: Donley, David W., et al.
Publicado: (2021)

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)
por: Friedrich, Annabelle, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer
por: Kong, Yanjie, et al.
Publicado: (2022)

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer
por: Losson, Hélène, et al.
Publicado: (2016)

Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
por: Zou, Yi, et al.
Publicado: (2013)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington’s disease
por: Stepanova, P., et al.
Publicado: (2023)

Chromatin remodeling induced by histone deacetylase inhibitors (HDACis) in HeLa, NIH 3T3 and HepG2 cells
por: Felisbino, Marina B, et al.
Publicado: (2013)

Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure
por: Qiu, Xiaodi, et al.
Publicado: (2019)

Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington’s disease
por: Islam, Jaisan, et al.
Publicado: (2021)

Pimelic acid–urea (1/2)
por: Xu, Wei, et al.
Publicado: (2011)

Correction: Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
Publicado: (2014)

Targeting Huntington’s disease through histone deacetylases
por: Gray, Steven G.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Adeno-Associated Viral Vector Serotype DJ-Mediated Overexpression of N171-82Q-Mutant Huntingtin in the Striatum of Juvenile Mice Is a New Model for Huntington’s Disease
por: Jang, Minhee, et al.
Publicado: (2018)

A transcriptomic dataset used to derive biomarkers of chemically induced histone deacetylase inhibition (HDACi) in human TK6 cells
por: Cho, Eunnara, et al.
Publicado: (2021)

An Optimization of AAV-82Q-Delivered Rat Model of Huntington’s Disease
por: So, Kyoung-Ha, et al.
Publicado: (2020)

Correction: Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays
por: Noor, Zainab, et al.
Publicado: (2015)

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model
por: Sandi, Chiranjeevi, et al.
Publicado: (2011)

Correction to: Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis
por: Schmidt, Oxana, et al.
Publicado: (2022)

Correction: Histone Deacetylase Inhibition Enhances Tissue Plasminogen Activator Release Capacity in Atherosclerotic Man
por: Svennerholm, Kristina, et al.
Publicado: (2015)

Correction to: HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines
por: Iveland, Tobias S., et al.
Publicado: (2021)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Correction to ‘Histone deacetylase (Rpd3) regulates Drosophila early brain development via regulation of Tailless’
por: Das, Paromita, et al.
Publicado: (2020)

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice
por: Hecklau, Katharina, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Publisher Correction: Structural and chemical biology of deacetylases for carbohydrates, proteins, small molecules and histones
por: Bürger, Marco, et al.
Publicado: (2019)

Correction to Lancet Neurol 2020; 19: 481–82
Publicado: (2020)

Correction to Lancet Psychiatry 2020; 7: 875–82
Publicado: (2020)

Correction to Lancet Neurol 2018; 17: 1061–82
Publicado: (2021)

Correction to Lancet Psychiatry 2021; 8: 871–82
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d5bmmath24kgubsk6t815bkv75